nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulpiride—DRD3—Gilles de la Tourette syndrome	0.552	0.591	CbGaD
Sulpiride—DRD2—Gilles de la Tourette syndrome	0.382	0.409	CbGaD
Sulpiride—DRD3—Dopamine receptors—DRD4—Gilles de la Tourette syndrome	0.00529	0.107	CbGpPWpGaD
Sulpiride—DRD3—Dopamine receptors—DRD2—Gilles de la Tourette syndrome	0.00493	0.1	CbGpPWpGaD
Sulpiride—DRD2—Dopamine receptors—DRD3—Gilles de la Tourette syndrome	0.00417	0.0847	CbGpPWpGaD
Sulpiride—DRD2—Dopamine receptors—DRD4—Gilles de la Tourette syndrome	0.00405	0.0822	CbGpPWpGaD
Sulpiride—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.00334	0.0679	CbGpPWpGaD
Sulpiride—Alizapride—DRD2—Gilles de la Tourette syndrome	0.00206	0.204	CrCbGaD
Sulpiride—Remoxipride—DRD4—Gilles de la Tourette syndrome	0.00169	0.167	CrCbGaD
Sulpiride—DRD3—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.00168	0.0341	CbGpPWpGaD
Sulpiride—DRD3—Nicotine Activity on Dopaminergic Neurons—DRD2—Gilles de la Tourette syndrome	0.00156	0.0318	CbGpPWpGaD
Sulpiride—Remoxipride—DRD3—Gilles de la Tourette syndrome	0.00145	0.144	CrCbGaD
Sulpiride—DRD3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00141	0.0287	CbGpPWpGaD
Sulpiride—Amisulpride—DRD3—Gilles de la Tourette syndrome	0.00139	0.138	CrCbGaD
Sulpiride—DRD2—Nicotine Activity on Dopaminergic Neurons—DRD3—Gilles de la Tourette syndrome	0.00132	0.0269	CbGpPWpGaD
Sulpiride—DRD2—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.00128	0.0261	CbGpPWpGaD
Sulpiride—DRD3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00117	0.0237	CbGpPWpGaD
Sulpiride—DRD3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00109	0.0221	CbGpPWpGaD
Sulpiride—DRD2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00108	0.0219	CbGpPWpGaD
Sulpiride—Remoxipride—DRD2—Gilles de la Tourette syndrome	0.00101	0.0997	CrCbGaD
Sulpiride—DRD3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000983	0.02	CbGpPWpGaD
Sulpiride—Amisulpride—DRD2—Gilles de la Tourette syndrome	0.000965	0.0956	CrCbGaD
Sulpiride—DRD2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000922	0.0187	CbGpPWpGaD
Sulpiride—DRD2—Hypothetical Network for Drug Addiction—DRD4—Gilles de la Tourette syndrome	0.000917	0.0186	CbGpPWpGaD
Sulpiride—DRD3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000916	0.0186	CbGpPWpGaD
Sulpiride—DRD2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000895	0.0182	CbGpPWpGaD
Sulpiride—Remoxipride—HTR2A—Gilles de la Tourette syndrome	0.000777	0.0771	CrCbGaD
Sulpiride—DRD2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000775	0.0157	CbGpPWpGaD
Sulpiride—DRD3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000763	0.0155	CbGpPWpGaD
Sulpiride—DRD2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000752	0.0153	CbGpPWpGaD
Sulpiride—Amisulpride—HTR2A—Gilles de la Tourette syndrome	0.000745	0.0739	CrCbGaD
Sulpiride—DRD3—nervous system—Gilles de la Tourette syndrome	0.000703	0.104	CbGeAlD
Sulpiride—DRD3—central nervous system—Gilles de la Tourette syndrome	0.000677	0.1	CbGeAlD
Sulpiride—DRD3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000641	0.013	CbGpPWpGaD
Sulpiride—DRD2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000584	0.0119	CbGpPWpGaD
Sulpiride—CA12—nervous system—Gilles de la Tourette syndrome	0.000548	0.0811	CbGeAlD
Sulpiride—DRD3—brain—Gilles de la Tourette syndrome	0.000537	0.0795	CbGeAlD
Sulpiride—CA12—central nervous system—Gilles de la Tourette syndrome	0.000528	0.0781	CbGeAlD
Sulpiride—DRD3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.000519	0.0105	CbGpPWpGaD
Sulpiride—DRD2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000491	0.00997	CbGpPWpGaD
Sulpiride—CA6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000452	0.00919	CbGpPWpGaD
Sulpiride—CA12—brain—Gilles de la Tourette syndrome	0.000419	0.062	CbGeAlD
Sulpiride—CA12—Metabolism—HDC—Gilles de la Tourette syndrome	0.000391	0.00794	CbGpPWpGaD
Sulpiride—DRD2—midbrain—Gilles de la Tourette syndrome	0.000362	0.0535	CbGeAlD
Sulpiride—CA2—midbrain—Gilles de la Tourette syndrome	0.000342	0.0507	CbGeAlD
Sulpiride—DRD3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.000339	0.00688	CbGpPWpGaD
Sulpiride—BCHE—midbrain—Gilles de la Tourette syndrome	0.000328	0.0485	CbGeAlD
Sulpiride—CA2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000299	0.00607	CbGpPWpGaD
Sulpiride—DRD2—nervous system—Gilles de la Tourette syndrome	0.000297	0.044	CbGeAlD
Sulpiride—DRD2—central nervous system—Gilles de la Tourette syndrome	0.000286	0.0424	CbGeAlD
Sulpiride—CA2—nervous system—Gilles de la Tourette syndrome	0.000282	0.0417	CbGeAlD
Sulpiride—DRD3—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000276	0.0056	CbGpPWpGaD
Sulpiride—CA2—central nervous system—Gilles de la Tourette syndrome	0.000271	0.0401	CbGeAlD
Sulpiride—BCHE—nervous system—Gilles de la Tourette syndrome	0.00027	0.0399	CbGeAlD
Sulpiride—BCHE—central nervous system—Gilles de la Tourette syndrome	0.00026	0.0384	CbGeAlD
Sulpiride—DRD3—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000257	0.00521	CbGpPWpGaD
Sulpiride—BCHE—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000255	0.00517	CbGpPWpGaD
Sulpiride—CA9—Metabolism—HDC—Gilles de la Tourette syndrome	0.000252	0.00512	CbGpPWpGaD
Sulpiride—DRD3—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000243	0.00494	CbGpPWpGaD
Sulpiride—DRD2—brain—Gilles de la Tourette syndrome	0.000227	0.0336	CbGeAlD
Sulpiride—DRD3—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000227	0.0046	CbGpPWpGaD
Sulpiride—DRD3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000226	0.00458	CbGpPWpGaD
Sulpiride—DRD2—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000217	0.00441	CbGpPWpGaD
Sulpiride—CA2—brain—Gilles de la Tourette syndrome	0.000215	0.0318	CbGeAlD
Sulpiride—DRD2—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000211	0.00428	CbGpPWpGaD
Sulpiride—DRD3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00021	0.00427	CbGpPWpGaD
Sulpiride—BCHE—brain—Gilles de la Tourette syndrome	0.000206	0.0305	CbGeAlD
Sulpiride—BCHE—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000195	0.00396	CbGpPWpGaD
Sulpiride—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000193	0.00393	CbGpPWpGaD
Sulpiride—DRD2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000192	0.00389	CbGpPWpGaD
Sulpiride—DRD2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000186	0.00378	CbGpPWpGaD
Sulpiride—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00018	0.00366	CbGpPWpGaD
Sulpiride—DRD2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000178	0.00361	CbGpPWpGaD
Sulpiride—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000173	0.00351	CbGpPWpGaD
Sulpiride—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000152	0.00309	CbGpPWpGaD
Sulpiride—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000148	0.003	CbGpPWpGaD
Sulpiride—DRD3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000147	0.00299	CbGpPWpGaD
Sulpiride—DRD3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000147	0.00299	CbGpPWpGaD
Sulpiride—BCHE—Metabolism—HDC—Gilles de la Tourette syndrome	0.000141	0.00287	CbGpPWpGaD
Sulpiride—DRD3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000137	0.00279	CbGpPWpGaD
Sulpiride—DRD3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000126	0.00256	CbGpPWpGaD
Sulpiride—DRD2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000116	0.00236	CbGpPWpGaD
Sulpiride—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000113	0.00229	CbGpPWpGaD
Sulpiride—DRD2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000113	0.00229	CbGpPWpGaD
Sulpiride—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	9.65e-05	0.00196	CbGpPWpGaD
Sulpiride—DRD3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	9.61e-05	0.00195	CbGpPWpGaD
Sulpiride—DRD3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8.32e-05	0.00169	CbGpPWpGaD
Sulpiride—DRD3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.75e-05	0.00157	CbGpPWpGaD
Sulpiride—DRD3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.56e-05	0.00153	CbGpPWpGaD
Sulpiride—DRD2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	7.35e-05	0.00149	CbGpPWpGaD
Sulpiride—DRD3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	7.04e-05	0.00143	CbGpPWpGaD
Sulpiride—DRD2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.56e-05	0.00133	CbGpPWpGaD
Sulpiride—DRD2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.37e-05	0.00129	CbGpPWpGaD
Sulpiride—DRD2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.96e-05	0.00121	CbGpPWpGaD
Sulpiride—DRD2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.78e-05	0.00117	CbGpPWpGaD
Sulpiride—DRD3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.43e-05	0.0011	CbGpPWpGaD
Sulpiride—DRD3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.93e-05	0.001	CbGpPWpGaD
Sulpiride—DRD3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.46e-05	0.000906	CbGpPWpGaD
Sulpiride—DRD3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.16e-05	0.000844	CbGpPWpGaD
Sulpiride—DRD2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.15e-05	0.000844	CbGpPWpGaD
Sulpiride—DRD2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.77e-05	0.000766	CbGpPWpGaD
Sulpiride—DRD2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.52e-05	0.000714	CbGpPWpGaD
Sulpiride—DRD2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.42e-05	0.000694	CbGpPWpGaD
Sulpiride—DRD3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.91e-05	0.000591	CbGpPWpGaD
Sulpiride—DRD2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.23e-05	0.000453	CbGpPWpGaD
